Potential teratogenic effects of allopurinol: A case report

American Journal of Medical Genetics, Part A

Volumn 155, Issue 9, 2011, Pages 2247-2252

  Kozenko, Mariya ^a   Grynspan, David ^a   Oluyomi Obi, Titi ^a   Sitar, Daniel ^a   Elliott, Alison M ^a   Chodirker, Bernard N ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Allopurinol; Multiple malformations; Mycophenolate mofetil; Teratogen

Indexed keywords

ALLOPURINOL;

ARTICLE; AUTOPSY; BRAIN VENTRICLE DILATATION; CASE REPORT; CLEFT LIP PALATE; COLOBOMA; CONGENITAL DIAPHRAGM HERNIA; CORPUS CALLOSUM AGENESIS; CRYPTORCHISM; DRUG EFFECT; EXTERNAL AUDITORY CANAL; HEART FAILURE; HUMAN; HYPERTELORISM; INFANT; KIDNEY AGENESIS; LUNG AGENESIS; LUNG HYPOPLASIA; MALE; MICROGNATHIA; MICROPHTHALMIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE HYPOPLASIA; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY FAILURE; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ABNORMALITIES, MULTIPLE; ALLOPURINOL; ANTIMETABOLITES; FEMALE; HUMANS; INFANT, NEWBORN; KIDNEY CALCULI; MALE; MYCOPHENOLIC ACID; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; PURINES; TERATOGENS;

EID: 84860408408     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.34139     Document Type: Article

References (41)

1. Anderka MT, Lin AE, Abuelo DN, Mitchell AA, Rasmussen SA. 2009. Reviewing the evidence for mycophenolate mofetil as a new teratogen: Case report and review of the literature. Am J Med Genet Part A 149A: 1241-1248.
2. Ang GS, Simpson SA, Reddy AR. 2008. Mycophenolate mofetil embryopathy may be dose and timing dependent. Am J Med Genet Part A 146A: 1963-1966.
3. Armenti VT, Radomski JS, Moritz MJ, Gaughan WJ, Hecker WP, Lavelanet A. McGrory CH. Cosica LA. 2004. Report from the National Transplantation Pregnancy Registry (NTPR): Outcomes of pregnancy after transplantation. Clin Transpl 103-114.
4. Beck AE, Hudgins L, Hoyme HE. 2005. Autosomal dominant microtia and ocular coloboma: New syndrome or an extension of the oculo-auriculo-vertebral spectrum? Am J Med Genet Part A 134A: 359-362.
5. Blair B, Fabrizio M. 2000. Pharmacology for renal calculi. Expert Opin Pharmacother 1: 435-441.
6. Bragonier JR, Roesky N, Carver MJ. 1964. Teratogenesis: Effects of substituted purines and the influence of 4-hydroxypyrazolopyrimidine in the rat. Proc Soc Exp Biol Med 116: 685-688.
7. Breedveld FC, Dayer JM. 2000. Leflunomide: Mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 59: 841-849.
8. Chambers CD, Johnson DL, Robinson LK, Braddock SR, Xu R, Lopez-Jimenez J, Mirrasoul N, Salas E, Luo YJ, Jin S, Jones KL. Organization of Teratology Information Specialists Collaborative Research Group. 2010. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum 62: 1494-1503.
9. Chaube S, Kreis W, Uchida K, Murphy ML. 1968. The teratogenic effect of 1-beta-D-arabinofuranosylcytosine in the rat. Protection by deoxycytidine. Biochem Pharmacol 17: 1213-1216.
10. Chen YK, Wu FJ, Lin HC. 2010. Maternal gout associated with increased risk of low birth weight and preterm birth. Int J Gynaecol Obstet 109: 157-158.
11. Donnai D, Barrow M. 1993. Diaphragmatic hernia, exomphalos, absent corpus callosum, hypertelorism, myopia, and sensorineural deafness: A newly recognized autosomal recessive disorder? Am J Med Genet 47: 679-682.
12. Doray B, Girard-Lemaire F, Gasser B, Baldauf JJ, De Geeter B, Spizzo M, Zeidan C, Flori E. 2002. Pallister-Killian syndrome: Difficulties of prenatal diagnosis. Prenat Diagn 22: 470-477.
13. Farquharson CAJ, Butler R, Hill A, Belch JJF, Struthers AD. 2002. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 106: 221-226.
14. Friedman JM, Polifka JE. 2001. TERIS. Micromedex Reproductive Risk Information System (REPRORISK). Englewood, Colorado: Thomson MICROMEDEX.
15. Fryns JP. 1987. Fryns syndrome: A variable MCA syndrome with diaphragmatic defects, coarse face, and distal limb hypoplasia. J Med Genet 24: 271-274.
16. Fujii T, Nishimura H. 1972. Comparison of teratogenic action of substances related to purine metabolism in mouse embryos. Jpn J Pharmacol 22: 201-206.
17. Fukushima R, Kanamori S, Hirashiba M, Hishikawa A, Muranaka RI, Kaneto M, Nakamura K, Kato I. 2007. Teratogenacity study of the dihydroorotate-dehydrogenase inihibitor and protein tyrosine kinase inhibitor Lefunomide in mice. Reprod Toxicol 24: 310-316.
18. Gülmezoǧlu AM, Hofmeyr GJ, Oosthuisen MM. 1997. Antioxidants in the treatment of severe pre-eclampsia: An explanatory randomised controlled trial. Br J Obstet Gynaecol 104: 689-696.
19. Huang SY, Chueh HY, Shaw SW, Shih JC, Cheng PJ. 2008. Sonographic diagnosis of fetal malformations associated with mycophenolate mofetil exposure in utero. Am J Obstet Gynecol 199: e6-e8.
20. Kallen B, Westgren M, Aberg A, Otterblad Olausson P. 2005. Pregnancy outcome after maternal organ transplantation in Sweden. Br J Obstet Gynaecol 112: 904-909.
21. LeRay C, Coulomb A, Elefant E, Frydman R, Audibert F. 2004. Mycophenolate mofetil in pregnancy after renal transplantation: A case of major fetal malformations. Obstet Gynecol 103: 1091-1094.
22. Miller M, Fineman R, Smith DW. 1979. Postaxial acrofacial dysostosis syndrome. J Pediatr 95: 970-975.
23. Milunsky A, Gaef JW, Gaynor MF Jr. 1968. Methotrexate induced congenital malformations. J Pediatr 72: 790-795.
24. Naden RP, Redman CW. 1985. Antihypertensive drugs in pregnancy. Clin Perinatol 12: 521-538.
25. Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. 2010. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: A randomized, placebo-controlled crossover trial. Lancet 375: 2161-2167.
26. Ozkan G, Ulusoy S, Sönmez M, Kaynar K, Karagülle M. 2010. Treatment of tumor lysis syndrome with the highest known uric acid level. Ren Fail 32: 895-898.
27. Pacher P, Nivorozhkin A, Szabo C. 2006. Therapeutic effects of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol. Pharmacol Revs 58: 87-114.
28. Parisi MA, Zayed H, Slavotinek AM, Rutledge JC. 2009. Congenital diaphragmatic hernia and microtia in a newborn with mycophenolate mofetil (MMF) exposure: Phenocopy for Fryns syndrome or broad spectrum of teratogenic effects? Am J Med Genet Part A 149A: 1237-1240.
29. Perez-Aytes A, Ledo A, Boso V, Saenz P, Roma E, Poveda JL, Vento M. 2008. In utero exposure to mycophenolate mofetil: A characteristic phenotype? Am J Med Genet Part A 146A: 1-7.
30. Pergola PE, Kancharla A, Riley DJ. 2001. Kidney transplantation during the first trimester of pregnancy: Immunosuppression with mycophenolate mofetil, tacrolimus and prednisone. Transplantation 71: 994-997.
31. Ransom JT. 1995. Mechanism of action of mycophenolate mofetil. Ther Drug Monit 17: 681-684.
32. Schoner K, Steinhard J, Figiel J, Rehder H. 2008. Severe facial clefts in acrofacial dystosis: A consequence of prenatal exposure to mycophenolate mofetil? Obstet Gynecol 111: 483-486.
33. Sebaaly ZE, Charpentier B, Snanoudj R. 2007. Fetal malformations associated with mycophenolate mofetil for lupus nephritis. Nephrol Dial Transplant 22: 2722.
34. Sifontis NM, Coscia LA, Constantinescu S, Lavelanet A, Moritz MJ, Armenti VT. 2006. Pregnancy outcomes in solid organ transplant with exposure to mycophenolate mofetil or sirolimus. Transplantation 82: 1698-1702.
35. Spézia F, Fournex R, Vannier B. 1992. Action of allopurinol and aspirin on rat whole-embryo cultures. Toxicology 72: 239-250.
36. Stoll C, Alembik Y, Dott B, Roth MP. 2008. Associated malformations in cases with congenital diaphragmatic hernia. Genet Couns 19: 331-339.
37. Tasse C, Böhringer S, Fischer S, Lüdecke HJ, Albrecht B, Horn D, Janecke A, Kling R, König R, Lorenz B, Majewski F, Maeyens E, Meinecke P, Mitulla B, Mohr C, Preischl M, Umstadt H, Kohlhase J, Gillessen-Kaesbach G, Wieczorek D. 2005. Oculo-auriculo-vertebral spectrum (OAVS): Clinical evaluation and severity scoring of 53 patients and proposal for a new classification. Eur J Med Genet 48: 397-411.
38. Tjeertes IFA, Bastiaans DET, van Ganzewinkel CJLM, Zegers SHJ. 2007. Neonatal anemia and hydrops fetalis after maternal mycophenolate mofetil use. J Perinatol 27: 62-64.
39. Velinov M, Zellers N. 2008. The fetal mycophenolate mofetil syndrome. Clin Dysmorphol 17: 77-78.
40. Vila JHA, da Silva JP, Guilhen CJ, Baumgratz JF, da Fonseca L. 2008. Even low dose of mycophenolate mofetil in a mother recipient of heart transplant can seriously damage the fetus. Transplantation 86: 369-370.
41. Yedlinsky NT, Morgan FC, Whitecar PW. 2005. Anomalies associated with failed methotrexate and misoprostol termination. Obstet Gynecol 105: 1203-1205.